Opca Bolnica Karlovac
- Address
- lock Available on a paid plan
Opca Bolnica Karlovac - Cardiometabolic and Respiratory Disease Research
Opca Bolnica Karlovac is a clinical research center focused on investigating innovative therapies for complex cardiometabolic and respiratory conditions. The center specializes in evaluating novel pharmacological interventions aimed at improving outcomes for patients with chronic diseases that significantly impact quality of life and long-term health.
- Chronic Obstructive Pulmonary Disease (COPD) management with advanced triple therapy combinations
- Severe hypertriglyceridemia treatment and lipid metabolism disorders
- Obesity and type 2 diabetes weight management interventions
The research facility has demonstrated particular expertise in conducting Phase III trials evaluating add-on therapies for COPD exacerbation prevention, as well as studies examining novel approaches to managing severe metabolic dyslipidemia. Additionally, the center investigates cutting-edge treatments for weight reduction in patients with concurrent obesity and type 2 diabetes, contributing to the advancement of precision medicine in cardiometabolic care. This diverse portfolio reflects the center's commitment to addressing multiple interconnected chronic disease states that affect the Croatian and broader European patient population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S3active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S6trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Opca Bolnica Karlovac
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Dose-Finding Study to Evaluate the Efficacy and Safety of Once-Weekly Subcutaneous NNC0662-0419 in Participants with Type 2 Diabetes | Novo Nordisk A/S | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 2 | Unknown | 2026-04-28 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.